The 39 rating InvestorsObserver gives to Summit Therapeutics Inc (SMMT) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 38 percent of stocks in the Biotechnology industry, SMMT’s 39 overall rating means the stock scores better than 39 percent of all stocks.
SMMT has an Overall Score of 39. Find out what this means to you and get the rest of the rankings on SMMT!
Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What's Happening With Summit Therapeutics Inc Stock Today?
Summit Therapeutics Inc (SMMT) stock is trading at $1.99 as of 3:44 PM on Monday, Aug 14, an increase of $0.27, or 15.7% from the previous closing price of $1.72. The stock has traded between $1.69 and $2.04 so far today. Volume today is above average. So far 2,435,160 shares have traded compared to average volume of 1,121,256 shares.
Click Here to get the full Stock Report for Summit Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
